Tevogen Bio Holdings Inc. (TVGNW)Warren, United States | NasdaqCM
0.06 USD
0.00
(-1.610%) ⇩
(July 13, 2026, 3:42 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:41 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic balance sheet and relentless cash burn. The company carries nearly $9.5 million in debt against a mere $692k in cash, resulting in a current ratio of 0.295—a clear sign of imminent liquidity distress. Operating cash flow is draining at -$11.7 million annually, while free cash flow is -$3.1 million, indicating the business is consuming capital faster than it can generate it. This financial fragility is compounded by a negative book value of -$4.47, suggesting the assets on the ledger do not cover liabilities. While the stock recently saw volatility with a gap up and down, the underlying fundamentals offer no support for a recovery; the statistical forecast also leans negative for the coming month. There is no dividend to provide any cushion, and the equity is effectively worthless given the insolvency risks. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.000000 |
| AutoETS | 0.000000 |
| MSTL | 0.000804 |
| AutoTheta | 0.019074 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 0.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.259 |
| Excess Kurtosis | -1.20 |
| Attribute | Value |
|---|---|
| Beta | 0.22 |
| Previous Name | Semper Paratus Acquisition Corporation |
| Website | https://tevogen.com |
| Attribute | Value |
|---|---|
| Address1 | 15 Independence Boulevard |
| Address2 | Suite #210 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 0.222 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -4.472 |
| City | Warren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.055 |
| Current Ratio | 0.295 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.057 |
| Day Low | 0.0489 |
| Display Name | Tevogen Bio |
| Ebitda | -21,004,800 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.057 |
| Fifty Two Week High Change | -0.0020000003 |
| Fifty Two Week High Change Percent | -0.035087723 |
| Fifty Two Week Low | 0.0489 |
| Fifty Two Week Low Change | 0.006099999 |
| Fifty Two Week Low Change Percent | 0.124744356 |
| Fifty Two Week Range | 0.0489 - 0.057 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 1,074,053 |
| Free Cashflow | -3,168,028 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey. |
| Long Name | Tevogen Bio Holdings Inc. |
| Market | us_market |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_702249906 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -21,942,570 |
| Open | 0.045 |
| Operating Cashflow | -11,754,283 |
| Operating Margins | 0.0 |
| Phone | 877 838 6434 |
| Prev Name | Semper Paratus Acquisition Corporation |
| Previous Close | 0.0559 |
| Price Hint | 4 |
| Price To Book | -0.012298747 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.117 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00090000033 |
| Regular Market Change Percent | -1.6100185 |
| Regular Market Day High | 0.057 |
| Regular Market Day Low | 0.0489 |
| Regular Market Day Range | 0.0489 - 0.057 |
| Regular Market Open | 0.045 |
| Regular Market Previous Close | 0.0559 |
| Regular Market Price | 0.055 |
| Regular Market Time | 1,783,971,775 |
| Regular Market Volume | 159,012 |
| Return On Assets | -2.9442801 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Semper Paratus Acquisition Corp |
| Source Interval | 15 |
| State | NJ |
| Symbol | TVGNW |
| Total Cash | 692,305 |
| Total Cash Per Share | 0.165 |
| Total Debt | 9,472,709 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 159,012 |
| Website | https://tevogen.com |
| Zip | 7,059 |